This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Blood levels of Homocysteine are elevated in Alzheimer's disease (AD), and hyperhomocyteinemia may contribute to disease pathophysiology by vasculare and direct neurotoxic mechanisms. Homocyteine levels can be reduced by administration of high dose supplements of folic acid and vitamins B6 and B12. We propose a multicenter, randomized, controlled clinical trial to determine whether reduction of homocysteine levels with high dose folic acid/B6/B12 supplementation will slow the rate of cognitive decline in subjects with AD. This will be parallel design study, including two groups of unequal size: 60% of subjects will receive daily high-dose supplements (folic acid 5mg, vitamin B6 25mg, vitamin B12 1mg), and 40% will receive identical placebo; the duration of treatment will be 18 months. The primary outcome measure will be the longitudinal decline in the ADAScog. To power the trial to detect a 25% reduction of ADAScog decline (80% power, alpha+0.05, drop-out estimate 20%, drop-in estimate 10%), we will enroll a total of 400 subjects.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR010284-12
Application #
7607811
Study Section
Special Emphasis Panel (ZRR1-CR-8 (02))
Project Start
2007-03-01
Project End
2008-02-29
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
12
Fiscal Year
2007
Total Cost
$22,024
Indirect Cost
Name
Howard University
Department
Type
Schools of Medicine
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059
Mullins, Tanya L Kowalczyk; Li, Su X; Bethel, James et al. (2018) Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy. J Clin Virol 102:7-11
Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141
Doumatey, Ayo P; He, William J; Gaye, Amadou et al. (2018) Circulating MiR-374a-5p is a potential modulator of the inflammatory process in obesity. Sci Rep 8:7680
Guan, Yue; Roter, Debra L; Wolff, Jennifer L et al. (2018) The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns 101:817-823
Faruque, Mezbah U; Chen, Guanjie; Doumatey, Ayo P et al. (2017) Transferability of genome-wide associated loci for asthma in African Americans. J Asthma 54:1-8
Guan, Yue; Roter, Debra L; Erby, Lori H et al. (2017) Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927-935
Nandakumar, Priyanka; Lee, Dongwon; Richard, Melissa A et al. (2017) Rare coding variants associated with blood pressure variation in 15?914 individuals of African ancestry. J Hypertens 35:1381-1389
Lieberman, Richard; Armeli, Stephen; Scott, Denise M et al. (2016) FKBP5 genotype interacts with early life trauma to predict heavy drinking in college students. Am J Med Genet B Neuropsychiatr Genet 171:879-87
Christensen, Kurt D; Roberts, J Scott; Whitehouse, Peter J et al. (2016) Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 164:155-63
Armeli, Stephen; O'Hara, Ross E; Covault, Jon et al. (2016) Episode-specific drinking-to-cope motivation and next-day stress-reactivity. Anxiety Stress Coping 29:673-84

Showing the most recent 10 out of 205 publications